Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06XVN
|
|||
| Former ID |
DCL000802
|
|||
| Drug Name |
Farletuzumab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Phase 3 | [1] | |
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 3 | [2] | ||
| Company |
Morphotek
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Folate receptor alpha (FOLR1) | Target Info | Modulator | [3] |
| KEGG Pathway | Endocytosis | |||
| Reactome | COPII (Coat Protein 2) Mediated Vesicle Transport | |||
| Cargo concentration in the ER | ||||
| WikiPathways | Folate Metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022740) | |||
| REF 3 | Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.Gynecol Oncol.2013 Jun;129(3):452-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.